Jane Street Group LLC Has $192,000 Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Jane Street Group LLC trimmed its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 30.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,855 shares of the company’s stock after selling 6,940 shares during the period. Jane Street Group LLC’s holdings in Mineralys Therapeutics were worth $192,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of MLYS. Wellington Management Group LLP bought a new position in Mineralys Therapeutics in the 3rd quarter valued at $775,000. State Street Corp lifted its stake in shares of Mineralys Therapeutics by 4.0% during the third quarter. State Street Corp now owns 483,766 shares of the company’s stock valued at $5,858,000 after acquiring an additional 18,627 shares during the period. Polar Asset Management Partners Inc. acquired a new position in shares of Mineralys Therapeutics during the third quarter valued at $490,000. Ikarian Capital LLC bought a new position in Mineralys Therapeutics in the third quarter valued at about $2,180,000. Finally, Caligan Partners LP increased its position in Mineralys Therapeutics by 31.6% in the third quarter. Caligan Partners LP now owns 981,155 shares of the company’s stock worth $11,882,000 after purchasing an additional 235,397 shares during the period. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Stock Down 11.9 %

Shares of Mineralys Therapeutics stock opened at $9.87 on Monday. The business has a fifty day simple moving average of $12.64 and a 200 day simple moving average of $12.54. The stock has a market cap of $491.22 million, a PE ratio of -3.02 and a beta of 1.49. Mineralys Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period in the prior year, the business posted ($0.57) earnings per share. Analysts expect that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Insider Activity

In related news, insider David Malcom Rodman sold 25,482 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the sale, the insider now directly owns 135,974 shares of the company’s stock, valued at approximately $2,043,689.22. This represents a 15.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 33.24% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.